---
title: "CytoSorbents Receives Nasdaq Extension to Regain Compliance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281517355.md"
description: "CytoSorbents Corporation has received a 180-day extension from Nasdaq until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing. The company plans to monitor its share price closely and may consider a reverse stock split. Currently, the stock is rated as a Hold with a price target of $0.54, reflecting concerns over financial quality and regulatory risks. CytoSorbents focuses on blood purification therapies in critical care and cardiac surgery markets."
datetime: "2026-04-02T11:42:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281517355.md)
  - [en](https://longbridge.com/en/news/281517355.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281517355.md)
---

# CytoSorbents Receives Nasdaq Extension to Regain Compliance

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from Cytosorbents ( (CTSO) ) is now available.

On April 1, 2026, CytoSorbents Corporation disclosed that Nasdaq granted the company a 180-day extension, until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing. The company’s shares will remain listed during this period, and compliance will be restored if the stock closes at or above $1.00 for at least 10 consecutive trading days.

The extension follows an initial notice on October 2, 2025, that CytoSorbents had fallen below the required bid price, triggering a prior compliance deadline of March 31, 2026. Management plans to closely monitor the share price and is evaluating options to address the deficiency, including a potential reverse stock split, while acknowledging the risk that the stock could ultimately be delisted if compliance is not achieved.

The most recent analyst rating on (CTSO) stock is a Hold with a $0.54 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.

**Spark’s Take on CTSO Stock**

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

The score is held down primarily by weak financial quality (ongoing losses, negative free cash flow, and higher leverage) and bearish technicals (price below key moving averages with negative MACD). Earnings-call guidance and strong gross margins provide some support, but regulatory and liquidity/cash-burn risks keep the overall profile cautious.

To see Spark’s full report on CTSO stock, click here.

**More about Cytosorbents**

CytoSorbents Corporation operates in the medical technology and life sciences sector, focusing on blood purification therapies. Its primary products are designed to filter inflammatory mediators and toxins from the bloodstream, targeting critical care and cardiac surgery markets where effective blood purification can improve patient outcomes and reduce complications.

**Average Trading Volume:** 85,445

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $34.32M

For an in-depth examination of CTSO stock, go to TipRanks’ Overview page.

### Related Stocks

- [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md)

## Related News & Research

- [CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News](https://longbridge.com/en/news/286308377.md)
- [CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 | CTSO Stock News](https://longbridge.com/en/news/279801870.md)
- [Polymarket Launches Prediction Markets Tied to Private Companies](https://longbridge.com/en/news/286945839.md)
- [CVS Health: A Second Chance at Life Through Heart Transplant and Ongoing Care](https://longbridge.com/en/news/286777492.md)
- [Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology](https://longbridge.com/en/news/286769909.md)